WeVote

Bill

Bill

SB 901

Relating to: cost-sharing cap on insulin.

2025-2026 Regular Session Introduced by Kristin Dassler-Alfheim and 8 co-sponsors

Wisconsin bill caps patient insulin cost-sharing to improve medication affordability for diabetic residents with health insurance coverage.

Commissioner of Insurance report received pursuant to s.601.423(2), Wisconsin Statutes
0
WeVote Research Nonpartisan
Bill Summary · SB 901

Legislative bill overview

SB 901 establishes a cost-sharing cap on insulin for Wisconsin residents with health insurance. The bill limits the amount patients must pay out-of-pocket for insulin prescriptions, similar to caps that have been enacted in other states and at the federal level. The measure has bipartisan support and has moved through initial procedural steps including an Insurance Commissioner report.

Why is this important

Insulin is a life-sustaining medication for people with diabetes, and high out-of-pocket costs can force patients to ration doses or skip medications entirely, creating serious health risks. Wisconsin residents currently face variable insulin costs depending on their insurance plan and whether they have coverage at all. A cost-sharing cap directly addresses affordability for a significant portion of the state's diabetic population.

Potential points of contention

  • Cap amount specificity: The exact dollar limit or percentage cap is not detailed in this summary; stakeholders may disagree on what constitutes an adequate cap versus one that shifts costs to premiums
  • Insurance market impact: Insurers may argue caps increase premiums for all members or reduce plan options, while patient advocates contend savings justify any premium adjustments
  • Coverage scope: Uncertainty over whether the cap applies to all insulin types, all insurance plans (commercial, Medicaid, etc.), and whether it affects pharmacy benefit managers' negotiating leverage

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.